MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:RMTG)

0.0348 UNCHANGED
Delayed Quote Updated: 12:29 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RMTG

< Previous 1 2 Next >
News headline image
RMTG's ISSCA Division Announces Successful Santa Cruz, Bolivia Conference, October 23-24
A new country on ISSCA's calendar extends the division's market-by-market Latin American education cadence. 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21
A second Brazil event in a single year - a frequency ISSCA has not previously applied - underscores Brazil's priority alongside Cellgenic's permanent operations there. 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's ISSCA Division Expands Global Online Academy With Ten New Curriculum Tracks
A digital-first expansion scales physician education beyond ISSCA's in-person markets, diversifying the education segment toward higher-margin, travel-independent revenue. 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies
New ISSCA curriculum covers multiple adjunctive technologies used in longevity-focused practices and is intended to complement clinical capabilities Cellular Hope Institute is developing. 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides
The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model. 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico
Training Business Accelerates with Hundreds of Physicians from over 50 Countries at our Flagship Cancún Global Summit. ISSCA 125 Global Summit is scheduled to combine five ISSCA certification tracks... 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy
ISSCA's most comprehensive credential to date integrates regenerative medicine, biotechnology, longevity medicine, and artificial intelligence - a durable, multi-year physician-relationship asset. New... 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model
Physician-controlled lab-to-plan workflow, ISSCA protocol ingestion, licensed technology partnership, and clinic-facing SaaS and membership design - with the physician remaining the decision-maker 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements
Colombia is the third Latin American market in which Cellgenic has recently announced local commercial arrangements. Activity remains subject to applicable Colombian law and the terms of local... 
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
Cellgenic Establishes Local Commercial Presence in Brazil
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean Rooms
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 Results
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical Infrastructure
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative Medicine
From Regenerative Medical Technology Group
Via ACCESS Newswire
News headline image
RMTG Surges 93% in Revenue, 87% in Gross Profit and 70% in Operating Income for Q1 2026 vs Q1 2025
Via ACCESS Newswire
News headline image
RMTG Subsidiary Cellgenic Commences Full-Scale Manufacturing at First-of-Its-Kind
Via ACCESS Newswire
News headline image
RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit
Via ACCESS Newswire
News headline image
RMTG Subsidiary CELLGENIC Expands into Dominican Republic with New Distribution Partnership
Via ACCESS Newswire
News headline image
RMTG Expands into Brazil with Strategic Representation Agreement
Via ACCESS Newswire
News headline image
RMTG's ISSCA Regenerative Medicine Global Summit 2025 Concludes in Cancún with Full Attendance from 30+ Countries
Via ACCESS Newswire
News headline image
RMTG Partners with BKFC as Official Regenerative Medicine Provider
Via ACCESS Newswire
News headline image
RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story